- Home
- ARWR vs IBRX Comparison
ARWR vs IBRX Comparison
Compare ARWR & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARWR
- IBRX
- Stock Information
- Founded
- ARWR 2003
- IBRX 2014
- Country
- ARWR United States
- IBRX United States
- Employees
- ARWR N/A
- IBRX N/A
- Industry
- ARWR Biotechnology: Pharmaceutical Preparations
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARWR Health Care
- IBRX Health Care
- Exchange
- ARWR Nasdaq
- IBRX Nasdaq
- Market Cap
- ARWR 1.7B
- IBRX 2.4B
- IPO Year
- ARWR 1993
- IBRX N/A
- Fundamental
- Price
- ARWR $13.25
- IBRX $2.61
- Analyst Decision
- ARWR Buy
- IBRX Strong Buy
- Analyst Count
- ARWR 11
- IBRX 5
- Target Price
- ARWR $41.44
- IBRX $11.35
- AVG Volume (30 Days)
- ARWR 2.2M
- IBRX 7.3M
- Earning Date
- ARWR 05-08-2025
- IBRX 05-08-2025
- Dividend Yield
- ARWR N/A
- IBRX N/A
- EPS Growth
- ARWR N/A
- IBRX N/A
- EPS
- ARWR N/A
- IBRX N/A
- Revenue
- ARWR $2,500,000.00
- IBRX $14,745,000.00
- Revenue This Year
- ARWR $4,380.43
- IBRX $621.53
- Revenue Next Year
- ARWR $64.24
- IBRX $163.57
- P/E Ratio
- ARWR N/A
- IBRX N/A
- Revenue Growth
- ARWR N/A
- IBRX 2270.58
- 52 Week Low
- ARWR $9.57
- IBRX $2.28
- 52 Week High
- ARWR $30.41
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- ARWR 50.85
- IBRX 45.65
- Support Level
- ARWR $10.92
- IBRX $2.35
- Resistance Level
- ARWR $13.45
- IBRX $2.87
- Average True Range (ATR)
- ARWR 1.10
- IBRX 0.26
- MACD
- ARWR 0.41
- IBRX 0.01
- Stochastic Oscillator
- ARWR 94.85
- IBRX 37.96
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.